Burgess Julie has filed 4 insider transactions across 1 company since February 2023.
Most recent transaction: a grant/award of 150000 shares of Design Therapeutics, Inc. ($DSGN) on January 02, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | Design Therapeutics, Inc. | $DSGN | Burgess Julie | Chief Accounting Officer | A | Stock option (right to buy) | 150000 | $0.00 | 150,000.0000 | 56,963,757 | 9999.99% | 0.26% |
| Jan. 2, 2025 | Design Therapeutics, Inc. | $DSGN | Burgess Julie | Chief Accounting Officer | A | Stock option (right to buy) | 135000 | $0.00 | 135,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 2, 2024 | Design Therapeutics, Inc. | $DSGN | Burgess Julie | Chief Accounting Officer | A | Stock Option (right to buy) | 110000 | $0.00 | 110,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | Design Therapeutics, Inc. | $DSGN | Burgess Julie | Chief Accounting Officer | A | Stock Option (right to buy) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |